A Phase 3 interventional study of Teduglutide in Short Bowel Syndrome, sponsored by Shire. Completed at 5 sites in Japan. Open to participants aged 4 Months to 15 Years. Per ClinicalTrials.gov, last updated 2022-02-02.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 15th largest by enrollment, is one of 2 that started in 2017, is one of 16 in phase 3, and was the 12th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 4 Months to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2017.
This study's enrollment of 10 is below the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 14th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2017, is one of 17 in phase 3, and was the 13th registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if an investigational treatment (teduglutide) is safe and effective in Japanese children (age 4 months through 15 years of age) with SBS who are dependent on parenteral support. This study will also evaluate how teduglutide moves through the body (pharmacokinetics) and how it affects the body (pharmacodynamics).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For infants 4 to \<12 months corrected gestational age: Inability to significantly reduce PN/IV support, usually associated with minimal or no advance in enteral feeds (ie, 10% or less change in PN or advance in feeds) for at least 1 month prior to and during screening, as assessed by the investigator.
For children 1 to 15 years of age:
Inability to significantly reduce PN/IV support, usually associated with minimal or no advance in enteral feeds (ie, 10% or less change in PN or advance in feeds) for at least 3 months prior to and during screening, as assessed by the investigator.
Transient instability for events such as interruption of central access or treatment of sepsis is allowed if the PN/IV support returns to within 10% of baseline prior to the event.
Exclusion Criteria:
For infants 4 to \<12 months corrected gestational age at least 2 of any of the following parameters:
For children 1 to 15 years of age:
Alanine aminotransferase (ALT) >= 7x ULN
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive teduglutide 0.05 milligram per kilogram per day (mg/kg/day) subcutaneous (SC) injection once daily for 24 weeks.
Drug: Teduglutide
0.05 mg/kg/day SC injection once daily for 24 weeks.
Absolute Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data
Absolute change from baseline in PS volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period. Here, milliliter per kilogram per day is abbreviated as mL/kg/day.
Time frame: Baseline, EOT (up to Week 24)
Percent Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data
Percent change from baseline in PS volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: Baseline, EOT (up to Week 24)
Absolute Change From Baseline in Parenteral Support (PS) Caloric Intake at End of Treatment (EOT) Based on Dairy Data
Absolute change from baseline in PS caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).
Time frame: Baseline, EOT (up to Week 24)
Percent Change From Baseline in Parenteral Support (PS) Caloric Intake at End of Treatment (EOT) Based on Dairy Data
Percent change from baseline in PS caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: Baseline, EOT (up to Week 24)
Absolute Change From Baseline in Plasma Citrulline at End of Treatment (EOT)
Absolute change from baseline in plasma citrulline at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: Baseline, EOT (up to Week 24)
Percent Change From Baseline in Plasma Citrulline at End of Treatment (EOT)
Percent change from baseline in plasma citrulline at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: Baseline, EOT (up to Week 24)
Absolute Change From Baseline in Enteral Nutritional (EN) Volume at End of Treatment (EOT) Based on Dairy Data
Absolute change from baseline in EN volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: Baseline, EOT (up to Week 24)
Percent Change From Baseline in Enteral Nutritional (EN) Volume at End of Treatment (EOT) Based on Dairy Data
Percent change from baseline in EN volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: Baseline, EOT (up to Week 24)
Absolute Change From Baseline in Enteral Nutritional (EN) Caloric Intake at End of Treatment (EOT) Based on Dairy Data
Absolute change from baseline in EN caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: Baseline, EOT (up to Week 24)
Percent Change From Baseline in Enteral Nutritional (EN) Caloric Intake at End of Treatment (EOT) Based on Dairy Data
Percent change from baseline in EN caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: Baseline, EOT (up to Week 24)
Number of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 24
Number of participants who achieved at least 20% reduction in PS volume at Week 24 was reported.
Time frame: Week 24
Number of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at End of Treatment (EOT)
Number of participants who achieved at least 20% reduction in PS volume at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: EOT (up to Week 24)
Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning of Parenteral Support (PS) Volume at End of Treatment (EOT)
Number of participants who achieved at least 100% reduction in complete weaning of PS volume at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: EOT (up to Week 24)
Number of Participants Who Achieved Greater Than or Equal to (>=) 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 28
Number of participants who achieved \>= 20% reduction in PS volume at Week 28 was reported.
Time frame: Week 28
Absolute Change From End of Treatment (EOT) in Parenteral Support (PS) Volume at End of Study (EOS) Based on Dairy Data
Absolute change from EOT (up to Week 24) in PS volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: EOT (up to Week 24), EOS (up to Week 28)
Percent Change From End of Treatment (EOT) in Parenteral Support (PS) Volume at End of Study (EOS) Based on Dairy Data
Percent change from EOT (up to Week 24) in PS volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: EOT (up to Week 24), EOS (up to Week 28)
Absolute Change From End of Treatment (EOT) in Parenteral Support (PS) Caloric Intake at End of Study (EOS) Based on Dairy Data
Absolute change from EOT (up to Week 24) in PS caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: EOT (up to Week 24), EOS (up to Week 28)
Percent Change From End of Treatment (EOT) in Parenteral Support (PS) Caloric Intake at End of Study (EOS) Based on Dairy Data
Percent change from EOT (up to Week 24) in PS caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: EOT (up to Week 24), EOS (up to Week 28)
Absolute Change From End of Treatment (EOT) in Plasma Citrulline at End of Study (EOS)
Absolute change from EOT (up to Week 24) in plasma citrulline at EOS (up to Week 28) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: EOT (up to Week 24), EOS (up to Week 28)
Percent Change From End of Treatment (EOT) in Plasma Citrulline at End of Study (EOS)
Percent change from EOT (up to Week 24) in plasma citrulline at EOS (up to Week 28) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: EOT (up to Week 24), EOS (up to Week 28)
Absolute Change From End of Treatment (EOT) in Enteral Nutritional (EN) Volume at End of Study (EOS) Based on Dairy Data
Absolute change from EOT (up to Week 24) in EN volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: EOT (up to Week 24), EOS (up to Week 28)
Percent Change From End of Treatment (EOT) in Enteral Nutritional (EN) Volume at End of Study (EOS) Based on Dairy Data
Percent change from EOT (up to Week 24) in EN volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: EOT (up to Week 24), EOS (up to Week 28)
Absolute Change From End of Treatment (EOT) in Enteral Nutritional (EN) Caloric Intake at End of Study (EOS) Based on Dairy Data
Absolute change from EOT (up to Week 24) in EN caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: EOT (up to Week 24), EOS (up to Week 28)
Percent Change From End of Treatment (EOT) in Enteral Nutritional (EN) Caloric Intake at End of Study (EOS) Based on Dairy Data
Percent change from EOT (up to Week 24) in EN caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: EOT (up to Week 24), EOS (up to Week 28)
Absolute Change From Baseline in Number of Hours Per Day of Parenteral Support (PS) Usage at End of Treatment (EOT) Based on Dairy Data
Absolute change from baseline in number of hours per day of PS Usage at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: Baseline, EOT (up to Week 24)
Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment (EOT) Based on Dairy Data
Absolute change from baseline in number of days per Week of PS usage at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
Time frame: Baseline, EOT (up to Week 24)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An Adverse Event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened, or intensity increased after receiving the investigational product.
Time frame: From start of study drug administration up to EOS (up to Week 28)
Change From Baseline in Body Weight for Age Z-score at Week 28
Body weight was measured using age Z-score. A Z-score was defined as the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score at Week 28 was reported.
Time frame: Baseline, Week 28
Change From Baseline in Height for Age Z-score at Week 28
Height was measured using age Z-score. A Z-score was defined as the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at Week 28 was reported.
Time frame: Baseline, Week 28
Change From Baseline in Head Circumference for Age Z-score at Week 28
Head circumference was measured using age Z-score. A Z-score was defined as the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for age Z-score at Week 28 was reported.
Time frame: Baseline, Week 28
Number of Participants With Clinically Significant Changes in Vital Signs Reported as Treatment Emergent Adverse Events (TEAEs)
Vital sign assessments included pulse rate, blood pressure, or body temperature. Number of participants with clinically significant changes in vital signs by the investigator were recorded as TEAEs.
Time frame: From start of study drug administration up to EOS (up to Week 28)
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as Treatment Emergent Adverse Events (TEAEs)
12-lead ECG was performed. Any change in ECG assessments which were deemed to be clinically significant changes were recorded as TEAEs.
Time frame: From start of study drug administration up to EOS (up to Week 28)
Number of Participants With Clinically Significant Laboratory Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)
Clinical laboratory assessments included biochemistry, hematology, coagulation, urinalysis. The number of participants with clinically significant laboratory abnormalities were reported as TEAEs.
Time frame: From start of study drug administration up to EOS (up to Week 28)
Change From Baseline in the Average Urine Output at Week 28
Average urine output was recorded in measured volume at Week 28 was recorded.
Time frame: Baseline, Week 28
Change From Baseline in the Fecal Output at Week 28
Change from baseline in the fecal output (Average number of stools per day) at Week 28 was recorded.
Time frame: Baseline, Week 28
Number of Participants With Positive Specific Antibodies to Teduglutide
Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.
Time frame: From start of study drug administration up to EOS (up to Week 28)
Number of Participants With Clinically Significant Abnormal Findings in Gastrointestinal (GI) Specific Testing
GI specific testing included colonoscopy or sigmoidoscopy, abdominal ultrasound, fecal occult blood testing, upper GI series with small bowel follow-through (UGI/SBFT). EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period. Number of participants with clinically significant abnormal findings in gastrointestinal specific testing were reported.
Time frame: Baseline, EOT (up to Week 24)
Area Under the Concentration-time Curve at Steady State (AUCtau,ss) of Teduglutide in Plasma
Since only 2 sparse pharmacokinetics (PK) samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose
Maximum Plasma Concentration at Steady-state (Cmax,ss) of Teduglutide in Plasma
Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose
Minimum Plasma Concentration at Steady-state (Cmin.ss) of Teduglutide in Plasma
Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose
Time to Reach Maximum Observed Drug Concentration (Tmax) of Teduglutide in Plasma
Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose
Terminal-Phase Half-life (t1/2) of Teduglutide in Plasma
Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose
Apparent Clearance (CL/F) of Teduglutide
Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose
Apparent Volume of Distribution (V[Lambda z]/F) of Teduglutide
Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose
The study was conducted at 6 centers in Japan between 13 January 2017 (first participant first visit) and 21 January 2020 (last participant last visit).
| Milestone | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Started | 8 | 2 |
| Completed | 8 | 2 |
| Not completed | 0 | 0 |
Absolute change from baseline in PS volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period. Here, milliliter per kilogram per day is abbreviated as mL/kg/day.
| mL/kg/day | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Absolute Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data | -11.8 ± 8.47 | -26.2 ± 13.61 |
Percent change from baseline in PS volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Percent Change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data | -27.7 ± 31.79 | -26.7 ± 15.14 |
Absolute change from baseline in PS caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).
| kcal/kg/day | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Absolute Change From Baseline in Parenteral Support (PS) Caloric Intake at End of Treatment (EOT) Based on Dairy Data | -7.2 ± 8.70 | -13.8 ± 3.17 |
Percent change from baseline in PS caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From Baseline in Parenteral Support (PS) Caloric Intake at End of Treatment (EOT) Based on Dairy Data | -26.2 ± 33.00 | -25.7 ± 2.73 |
Absolute change from baseline in plasma citrulline at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Micromoles per liter (mcmol/L) | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Absolute Change From Baseline in Plasma Citrulline at End of Treatment (EOT) | 3.2 ± 4.28 | — |
Percent change from baseline in plasma citrulline at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From Baseline in Plasma Citrulline at End of Treatment (EOT) | 39.2 ± 39.46 | — |
Absolute change from baseline in EN volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| mL/kg/day | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Absolute Change From Baseline in Enteral Nutritional (EN) Volume at End of Treatment (EOT) Based on Dairy Data | 1.0 ± 7.14 | 0.6 ± 2.15 |
Percent change from baseline in EN volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From Baseline in Enteral Nutritional (EN) Volume at End of Treatment (EOT) Based on Dairy Data | 53.1 ± 111.01 | -23.2 ± 36.89 |
Absolute change from baseline in EN caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| kcal/kg/day | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Absolute Change From Baseline in Enteral Nutritional (EN) Caloric Intake at End of Treatment (EOT) Based on Dairy Data | 0.8 ± 5.60 | 0.3 ± 1.03 |
Percent change from baseline in EN caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From Baseline in Enteral Nutritional (EN) Caloric Intake at End of Treatment (EOT) Based on Dairy Data | 56.8 ± 117.88 | -24.2 ± 38.06 |
Number of participants who achieved at least 20% reduction in PS volume at Week 24 was reported.
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 24 | 4 | 1 |
Number of participants who achieved at least 20% reduction in PS volume at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at End of Treatment (EOT) | 4 | 1 |
Number of participants who achieved at least 100% reduction in complete weaning of PS volume at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning of Parenteral Support (PS) Volume at End of Treatment (EOT) | 1 | 0 |
Number of participants who achieved \>= 20% reduction in PS volume at Week 28 was reported.
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants Who Achieved Greater Than or Equal to (>=) 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 28 | 3 | 1 |
Absolute change from EOT (up to Week 24) in PS volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| mL/kg/day | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Absolute Change From End of Treatment (EOT) in Parenteral Support (PS) Volume at End of Study (EOS) Based on Dairy Data | 3.9 ± 7.06 | -3.8 ± 0.67 |
Percent change from EOT (up to Week 24) in PS volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From End of Treatment (EOT) in Parenteral Support (PS) Volume at End of Study (EOS) Based on Dairy Data | 9.8 ± 19.59 | -5.5 ± 2.35 |
Absolute change from EOT (up to Week 24) in PS caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| kcal/kg/day | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Absolute Change From End of Treatment (EOT) in Parenteral Support (PS) Caloric Intake at End of Study (EOS) Based on Dairy Data | 0.5 ± 6.16 | -4.0 ± 1.38 |
Percent change from EOT (up to Week 24) in PS caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From End of Treatment (EOT) in Parenteral Support (PS) Caloric Intake at End of Study (EOS) Based on Dairy Data | 3.5 ± 19.17 | -10.3 ± 4.40 |
Absolute change from EOT (up to Week 24) in plasma citrulline at EOS (up to Week 28) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Micromoles (mcM) | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Absolute Change From End of Treatment (EOT) in Plasma Citrulline at End of Study (EOS) | -2.9 ± 2.87 | — |
Percent change from EOT (up to Week 24) in plasma citrulline at EOS (up to Week 28) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From End of Treatment (EOT) in Plasma Citrulline at End of Study (EOS) | -20.0 ± 24.16 | — |
Absolute change from EOT (up to Week 24) in EN volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| mL/kg/day | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Absolute Change From End of Treatment (EOT) in Enteral Nutritional (EN) Volume at End of Study (EOS) Based on Dairy Data | -1.5 ± 3.24 | -2.8 ± 3.98 |
Percent change from EOT (up to Week 24) in EN volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From End of Treatment (EOT) in Enteral Nutritional (EN) Volume at End of Study (EOS) Based on Dairy Data | -22.1 ± 28.06 | -1.4 ± 8.25 |
Absolute change from EOT (up to Week 24) in EN caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| kcal/kg/day | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Absolute Change From End of Treatment (EOT) in Enteral Nutritional (EN) Caloric Intake at End of Study (EOS) Based on Dairy Data | -1.1 ± 2.64 | -1.4 ± 1.97 |
Percent change from EOT (up to Week 24) in EN caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From End of Treatment (EOT) in Enteral Nutritional (EN) Caloric Intake at End of Study (EOS) Based on Dairy Data | -22.1 ± 28.16 | -3.0 ± 6.03 |
Absolute change from baseline in number of hours per day of PS Usage at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Hours per day (hours/day) | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Absolute Change From Baseline in Number of Hours Per Day of Parenteral Support (PS) Usage at End of Treatment (EOT) Based on Dairy Data | -2.1 ± 4.16 | 0.0 ± 0.00 |
Absolute change from baseline in number of days per Week of PS usage at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.
| Days per week | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment (EOT) Based on Dairy Data | -0.9 ± 2.47 | 0.0 ± 0.00 |
An Adverse Event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened, or intensity increased after receiving the investigational product.
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 8 | 2 |
Body weight was measured using age Z-score. A Z-score was defined as the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score at Week 28 was reported.
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Body Weight for Age Z-score at Week 28 | 0.177 ± 0.3625 | 2.332 ± 1.1503 |
Height was measured using age Z-score. A Z-score was defined as the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at Week 28 was reported.
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Height for Age Z-score at Week 28 | 0.024 ± 0.4841 | 1.056 ± 0.6968 |
Head circumference was measured using age Z-score. A Z-score was defined as the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for age Z-score at Week 28 was reported.
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Head Circumference for Age Z-score at Week 28 | — | 1.559 ± 0.6116 |
Vital sign assessments included pulse rate, blood pressure, or body temperature. Number of participants with clinically significant changes in vital signs by the investigator were recorded as TEAEs.
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs Reported as Treatment Emergent Adverse Events (TEAEs) | 0 | 0 |
12-lead ECG was performed. Any change in ECG assessments which were deemed to be clinically significant changes were recorded as TEAEs.
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as Treatment Emergent Adverse Events (TEAEs) | 0 | 0 |
Clinical laboratory assessments included biochemistry, hematology, coagulation, urinalysis. The number of participants with clinically significant laboratory abnormalities were reported as TEAEs.
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants With Clinically Significant Laboratory Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs) | 0 | 0 |
Average urine output was recorded in measured volume at Week 28 was recorded.
| mL/kg/day | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in the Average Urine Output at Week 28 | -22.317 ± 34.8252 | -48.879 ± NA |
Change from baseline in the fecal output (Average number of stools per day) at Week 28 was recorded.
| Average number of stools per day | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in the Fecal Output at Week 28 | -0.64 ± 1.547 | 2.50 ± NA |
Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants With Positive Specific Antibodies to Teduglutide | 1 | 2 |
GI specific testing included colonoscopy or sigmoidoscopy, abdominal ultrasound, fecal occult blood testing, upper GI series with small bowel follow-through (UGI/SBFT). EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period. Number of participants with clinically significant abnormal findings in gastrointestinal specific testing were reported.
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants With Clinically Significant Abnormal Findings in Gastrointestinal (GI) Specific Testing | 0 | — |
Since only 2 sparse pharmacokinetics (PK) samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
No measurements were reported for this outcome.
Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
No measurements were reported for this outcome.
Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
No measurements were reported for this outcome.
Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
No measurements were reported for this outcome.
Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
No measurements were reported for this outcome.
Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
No measurements were reported for this outcome.
Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.
No measurements were reported for this outcome.
Collected over From start of study drug administration up to end of the study (up to Week 28). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total Children (Aged: 1 - 15 Years) | 0/8 (0%) | 6/8 (75%) | 8/8 (100%) |
| Infants (Corrected Gestational Age: 4 to < 12 Months) | 0/2 (0%) | 2/2 (100%) | 1/2 (50%) |
| Event | Total Children (Aged: 1 - 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| PyrexiaGeneral disorders | 0/8 | 2/2 |
| Device related infectionInfections and infestations | 3/8 | 1/2 |
| Upper respiratory tract infectionInfections and infestations | 0/8 | 1/2 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 0/8 | 1/2 |
| EnterocolitisGastrointestinal disorders | 2/8 | 0/2 |
| Medical device site infectionInfections and infestations | 2/8 | 0/2 |
| Abdominal painGastrointestinal disorders | 1/8 | 0/2 |
| Anaphylactic reactionImmune system disorders | 1/8 | 0/2 |
| Adenovirus infectionInfections and infestations | 1/8 | 0/2 |
| GastroenteritisInfections and infestations | 1/8 | 0/2 |
| Event | Total Children (Aged: 1 - 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 6/8 | 1/2 |
| EnterocolitisGastrointestinal disorders | 0/8 | 1/2 |
| Otitis mediaInfections and infestations | 0/8 | 1/2 |
| Vaccination complicationInjury, poisoning and procedural complications | 0/8 | 1/2 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 0/8 | 1/2 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/8 | 1/2 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 1/8 | 1/2 |
| Dry skinSkin and subcutaneous tissue disorders | 2/8 | 1/2 |
| RashSkin and subcutaneous tissue disorders | 4/8 | 0/2 |
| Injection site erythemaGeneral disorders | 3/8 | 0/2 |
Intention-to-treat (ITT) population consisted of all participants who were enrolled into the study and met all eligible criteria for the study.
| Age, Customized(Participants) | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) | Total |
|---|---|---|---|
| Count of participants | 8 | 2 | 10 |
| Sex: Female, Male(Participants) | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 7 | 1 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 2 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 8 | 2 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, ...).
Ran from Jan 2017 to primary completion in Jan 2020, 36 months.
Results were first posted in Feb 2021, 1 year after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 36 months is close to that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide